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1. Introduction
Since bone and joint inflammatory problems account for 50% 
of chronic diseases in developed countries,[1] there is an urgent 
demand for mechanically resistant and bone-compatible ortho-
pedic implants.[2–4] Implants often fail, requiring additional 
Novel approaches are needed to avoid bacterial infections following implant 
surgery. Here the use of mesoporous titania films (MTFs) for gentamicin 
loading and delivery and the surface functionalization of MFTs with human 
recombinant bone morphogenetic protein 2 (hrBMP-2) are discussed. 
Gentamicin is incorporated into the MTF pores by immersion of the porous 
materials in gentamicin solution while hrBMP-2 is adsorbed on top of the 
MTF. Contact angle and X-ray photoelectron spectroscopy measurements 
are performed to prove gentamicin loading and hrBMP-2 functionalization. 
An initial burst release of gentamicin takes place in physiological media 
followed by a prolonged release that lasts weeks. Such a release profile is 
highly appealing for bone implants where a high concentration of antibiotics 
is necessary during implant surgery while a lower antibiotic concentration 
is needed until tissue is regenerated. The MTFs loaded with gentamicin 
and functionalized with hrBMP-2 are effective against Staphylococcus 
aureus colonization, and the presence of hrBMP-2 enhances MC3T3-E1 
preosteoblastic cell attachment, proliferation, and differentiation.
Osseointegration
surgery and implant replacement, which 
are costly and compromise the health of 
the patient. A major reason for the failure 
of implants is the development of bacterial 
infections at the site of implant. During 
bone surgery, the surface of the implants 
is susceptible to bacterial infections that 
can lead to the formation of a biofilm and 
to a compromised immune response at the 
site of the implant. Aseptic loosening of 
the implants following surgery can result 
in the premature failure of the implant 
due to poor osseointegration.[5,6] Staphyloc ­
occus aureus is among the most common 
bacteria causing implant-associated infec-
tions and is considered to be a major, viru-
lent pathogen that colonizes and infects 
both hospitalized patients with decreased 
immunity and healthy immunocompe-
tent people.[7,8] Skin and mucous mem-
branes are excellent barriers against local 
tissue invasion by S. aureus, but if any of 
them is breached due to trauma or surgery, bacteria can enter 
the underlying tissue, creating their characteristic local abscess 
lesion.[9,10] Antibiotics are normally locally administered at the 
implant site, which effectively avoids the formation of bacterial 
colonies during surgery. However, there is a risk of bacterial 
colonization during the time bone tissue is being regenerated, 
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which last several weeks, until the protective capsule is formed 
and especially after surgery when the osseointegration pro-
cesses has started. To ensure the successful implant adaptation, 
a rational supply of antibiotics is needed and can be achieved by 
modifying the implant surface with antibiotics-loaded polymer 
coatings such as polyelectrolyte multilayers, brushes, or hydro-
gels.[11–14] However, the main challenge is to obtain a localized 
supply of the antibiotics with a two-phase release profile. An 
initial burst release at short times is highly desirable as, during 
surgery and at initial phase during bone formation, the risk of 
bacterial infection is larger, and a slow release that lasts weeks 
is required while the capsule is getting regenerated.
By favoring cell adhesion to the implant, tissue regen-
eration is promoted; thus, the risk of bacterial infections is 
diminished.[15–17] This can be achieved by different ways: 
modifying implant topography or using bioactive ions and 
growth factors. Mechanical properties, the resistance to cor-
rosion and wear, as well as osseointegration and biocompat-
ibility are some of the properties that the biomaterial should 
exhibit when selecting a candidate for bone replacement.[18] 
Depending on the type of bone, the modulus of elasticity 
varies between 4 to 30 GPa.[19] Titanium and titanium alloys 
are recognized as good materials for orthopedic implants due 
to their osseocompatibility and bone-bonding capacity.[18,20–25] 
Currently used commercial titanium implants satisfy the 
required mechanical properties with a Young’s modulus 
within the range of 100–120 GPa.[26] Coating the implant 
surface with a mesoporous film is an attractive method to 
improve biocompatibility, as rougher surfaces promote bone 
and implant interlocking.[23,24,27] Mesoporous materials have 
an ordered, homogeneous distribution of interconnected 
pores whose diameters are in the 2–50 nm range.[28–35] Titania 
can be synthesized as a mesoporous material without compro-
mising its mechanical properties,[36] which are fundamental 
for bone replacement. Mesoporous titania can be used for 
drug loading by soaking it in a drug solution, and once drugs 
are entrapped, their release is slowed by the necks that inter-
connect the mesopores.[37,38] Atefyekta et al.[39] have studied 
the loading and release of gentamicin, vancomycin, and dap-
tomycin from mesoporous titania films (MTFs) of pore sizes 
ranging from 4 to 7 nm, but the release of the antibiotics from 
the MTFs has been shown to occur within the first 80 min,[39] 
which is not desirable for implants, where an initial burst 
release followed by a prolonged one is needed.[16]
Here we show that the loading of MTFs with antibiotics 
and its surface functionalization with growth factor proteins 
improve the antibacterial properties of titania and promote the 
preosteoblasts proliferation and differentiation, as sketched 
in Figure 1. We used gentamicin (Chart S1, Supporting 
Information) to load a mesoporous titania film of 90 nm thick-
ness and 5.7 nm in pore diameter, prepared by spin coating 
through the evaporation-induced self-assembly (EISA) method. 
In contrast to previous studies,[40–43] we demonstrate here that 
while 36% of the gentamicin is released within the first 6 h, 
gentamicin release is prolonged over 35 days. The antibacterial 
properties of the mesoporous titania are further enhanced by 
immobilizing a growth factor—the human recombinant bone 
morphogenetic protein 2 (hrBMP-2)—on the surface of the 
film, favoring cell attachment and growth. While the antibac-
terial action of the gentamicin-loaded MTF was tested against 
S. aureus, the proliferation, adhesion, and differentiation assays 
were performed with the MC3T3-E1 preosteoblastic cell line.
2. Results and Discussion
2.1. MTF Synthesis and Functionalization with hrBMP-2  
and Gentamicin Loading
To obtain the mesoporous thin films, we implemented the well-
known EISA method that comprises hydrolysis and condensa-
tion of titania precursors in the presence of block copolymer 
Pluronic F127. The porous structure is confirmed by trans-
mission electron microscopy (TEM) and scanning electron 
microscopy (SEM) characterization (Figure 2a,b). The inset in 
Figure 2a shows the 2D-small angle X-ray scattering (2D-SAXS) 
pattern of the MTF. The elliptic shape of the pattern suggests 
the presence of multiple domains of locally ordered pores.[44] 
Calculated interplanar distances show interpore distances of 
11.5 and 3.9 nm in the (−110) and (110) planes, respectively. 
The contraction due to the calcination process at 350 °C is of 
65%, calculated from differences in the interpore distances 
at (−110) and (110) planes.[45] From the analysis of water 
adsorption–desorption isotherms (Figure 2d) obtained by envi-
ronmental ellipsomtric porosimetry (EEP), it can be concluded 
that the MTF has a porosity of 30.7% and a pore size of 5.7 nm 
in diameter connected by necks of 4.2 nm in diameter. The 
film thickness was of 80 nm, a value which is in agreement 
with the thickness of around 90 nm obtained from the SEM 
image of the transversal cut of the MTF (Figure 2c).
Nanoindentation measurements are presented in Figure S1 
(Supporting Information). They showed an elastic modulus of 
25 ± 5 GPa, smaller than the value for dense titanium surfaces, 
which is ranged between 100 and 120 GPa.[26] Nevertheless, it 
is in agreement with the range of elastic modules of bones, 
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Figure 1. MTF loaded with gentamicin and with hrBMP-2 on the surface 
to enhance MC3T3-E1 preosteoblastic cell attachment and differentiation 
and avoid S. aureus attachment.
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which lies between 4 and 30 GPa depending on bone type,[19] 
and values reported for porous titania films.[46]
MTFs were functionalized with hrBMP-2 and loaded with 
gentamicin. To confirm the presence of both hrBMP-2 and gen-
tamicin, the atomic percentage of S/Ti was quantified through 
high-resolution X-ray photoelectron spectroscopy (XPS) spectra 
in the spectral range of sulfur (S) and titanium (Ti) (Figure S2, 
Supporting Information). The peak corresponding to S 2p3/2 is 
more pronounced in the MTF loaded with antibiotic, coated with 
protein, or containing the mixture of both, as compared to the 
bare MTF. Although there was no S for the bare MTF, a S/Ti 
atomic relative percentage of 0.41 ± 0.09% was obtained, which 
corresponds to environmental contamination of the equipment. 
When the MTF was loaded with gentamicin, the S/Ti relative 
percentage increases to 2.03 ± 0.09%. If the MTF was func-
tionalized with hrBMP-2 prior to gentamicin loading, the S/Ti 
relative percentage is 3.44 ± 0.99%. The S/Ti ratio for the MTFs 
functionalized with hrBMP-2 and loaded with gentamicin was 
1.48 ± 0.32%. The decrease in S content for the mesoporous film 
with hrBMP-2 and gentamicin could be a consequence of partial 
removal of hrBMP-2 due to the loading conditions of gentamicin, 
as suggested by atomic force microscopy (AFM) experiments 
(see Figure 4g), and also may mean that hrBMP-2 adsorbed on 
the surface of MTFs partially blocks the access to the pores for 
gentamicin, diminishing the loading; however, the calculated 
standard error is high and the difference in the relative percentage 
is not significant between the MTF with gentamicin and the MTF 
with gentamicin and BMP-2. Additional proof of the loading and 
functionalization was obtained from contact angle measure-
ments. Figure 3 shows the changes in contact angle of water 
following hrBMP-2 functionalization and gentamicin loading. 
Bare MTF had a contact angle of 13.4° ± 0.30° (Figure 3a). When 
the MTF was loaded with gentamicin or functionalized with 
hrBMP-2, the contact angle changed to 73.15° ± 1.07° (Figure 3b) 
and 72.47° ± 2.60° (Figure 3c), respectively. For the MTF func-
tionalized with hrBMP-2 and loaded with gentamicin, the contact 
angle increased to 90.95° ± 2.19° (Figure 3d). Changes in contact 
angle confirmed the loading of gentamicin and the modification 
with the growth factor. Furthermore, the deposition of hrBMP-2 
on the MTFs was quantified by means of the quartz crystal 
microbalance with dissipation (QCMD). MTFs were assembled 
on top of quartz crystal sensors and exposed to hrBMP-2 solu-
tion in the QCMD chamber. For hrBMP-2 with a concentration 
of 1000 ng mL−1, we recorded a deposition of 60 ng cm−2. For the 
100 ng mL−1 solution, the QCMD was not capable of detecting 
the deposited mass of hrBMP-2. The changes in frequency 
for the deposition of 1000 ng mL−1 BMP-2 solution are shown 
in Figure S3 (Supporting Information). Mass was calculated 
applying the Sauerbrey equation.
Gentamicin loading is proved by release experiments and 
by measuring the antibacterial properties of the MTF after 
loading. Proliferation and differentiation assay confirm the 
Adv. Mater. Interfaces 2019, 1801648
Figure 2. Mesoporous titania film (MTF) structural characterization by electron microscopy, 2D-SAXS, and EEP. a) TEM image, inset: 2D-SAXS pattern; 
b) SEM image of the surface, c) SEM image of a transversal cut, and d) EEP of water vapor adsorption and desorption.
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presence of hrBMP-2 as well. Release experiments showed a 
release of 3.57 µg of gentamicin over 35 days. The release as we 
will show later reaches a plateau after 28 days. We can assume 
that all the gentamicin has been liberated after 35 days and that 
the amount of gentamicin released coincides with the loading. 
Moreover, more important than the loading is the amount of 
gentamicin that will be released from the mesoporous and will 
be responsible for the antibacterial action. We will take the total 
amount of released gentamicin as the actual effective loading of 
the mesoporous.
MTF displayed a smooth surface as confirmed by AFM 
imaging (Figure 4a–c), with a roughness of around 190 pm. 
When the protein was deposited on top of the MTF, roughness 
increases to 250 pm, meaning that the surface loses homoge-
neity but confirming the presence of hrBMP-2 (Figure 4f). The 
height profile singularities with a few nanometers in thickness 
can be recognized, which were not observed in the bare MTF. 
Phase image also confirms the presence of a different mate-
rial on top of the MTF (Figure 4e); when the height changes, 
a phase shift is also detected. When the MTF functionalized 
with hrBMP-2 was loaded with gentamicin, some hrBMP-2 
was loosed from the surface (Figure 4g) and the roughness 
decreased to 210 pm (Figure 4i). In the AFM image, the pres-
ence of proteins on the MTF is indicated with blue arrows.
2.2. Gentamicin Release from MTFs
The release profile of the gentamicin is plotted in Figure 5 as 
the total amount of released gentamicin (Figure 5a) and as the 
percentage of gentamicin released (Figure 5b). The percent-
ages are calculated assuming that after 35 days all gentamicin 
has been released from MTF in agreement with the plateau in 
the amount of released gentamicin observed after day 28 in 
Figure 5a. After 35 days 3.57 µg of gentamicin was released. 
In the figure we can observe that there was a fast release at ini-
tial times and within the first 6 h around the 36% of the total 
liberated gentamicin was released. This initial burst release 
is required to avoid bacteria to adhere and infect the implant 
during the surgery. This period is known to be the riskiest 
period for infection. After the burst release, a second slower 
and prolonged release took place. The second release profile is 
within the time frame required for the implant to be integrated 
in the tissue and for the formation of the protective fibrous 
capsule.[47] This second release step suggests that gentamicin 
is retained inside the pores interacting with the titania surface. 
Angelomé and Soler-Illia have shown that hydroxyl groups in 
dialcohols can be incorporated onto the MTFs by complexation 
of the Ti(IV) centers present in the pore surface.[48] Moreover, 
they have demonstrated that different amounts of dialcohols 
can be released in aqueous solution, depending on the medi-
um’s pH. Thus, gentamicin can be anchored to the titania sur-
face through oxo bridges due to the presence of three hydroxyl 
groups in the molecule, which would explain the slow release 
of gentamicin from MTFs. Gentamicin can also adhere to the 
MTF walls electrostatically. The presence of gentamicin linked 
to the pore walls by complexation and by electrostatic interac-
tions could explain the irregularities observed in the release 
profile. Gentamicin electrostatically bound should be more 
easily released as the interaction with titania is weaker than 
when gentamicin forms a complex through oxo bridges.
Our results on gentamicin liberation are quite different from 
Atefyekta et al.,[39] where a fast release of gentamicin takes place 
in around 80 min from mesoporous titania with pore sizes sim-
ilar to ours. A possible reason could be that the mesoporous 
structure in our films may have narrowed necks and higher 
Adv. Mater. Interfaces 2019, 1801648
Figure 3. Contact angle measurements. a) Bare MTF b) MTF with gentamicin, c) MTF with hrBMP-2 100 ng mL−1, and d) MTF with hrBMP-2 
100 ng mL−1 and gentamicin.
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tortuosity, resulting in only a 36% of gentamicin to be released 
as gentamicin diffusion through the pore mesh is more hin-
dered. Moreover, Atefyekta et al.[39] have measured gentamicin 
loading and release by QCMD from MTF deposited on top of 
CMD crystals. Both upload and release were measured from 
variations in the frequency of the crystal, and for release studies 
the authors apply a continuous flow of phosphate buffered 
saline (PBS) at a flux of 50 mL min−1, which is a relatively high 
flux and should trigger a faster liberation of gentamicin. In 
our case, the release is performed in static conditions. In their 
work, Atefyekta et al.[39] have recognized that the release is fast 
and related it to the methodology used for measuring antibi-
otic release, which seems a major reason for the differences 
observed between their results and the present work.
2.3. Biocompatibility and Bioactivity Evaluation
Initial cell adhesion on biomaterials plays a key role on cell pro-
liferation, migration, and differentiation. The focal adhesions 
(FA) and extracellular matrix (ECM) interactions involve inte-
grins that bind different ECM proteins with the external end 
and cytoskeleton via adapter proteins such as talin, α-actinin, 
filamin, and vinculin. FAs are based on this integrin-adapter 
protein−cytoskeleton complex. Osteoblasts anchor on substrate 
surface via integrin receptors, which are involved in processes 
named as “outside-in-signaling” and “inside-out-signaling” 
between the ECM and the cell. These pathways involving inte-
grins can regulate subsequent cell adhesion, migration, prolif-
eration, and differentiation.[49,50]
The MC3T3-E1 osteoblast precursor cell line was used to 
evaluate adhesion to the functionalized MTFs. Figures S4 and S5 
(Supporting Information) and Figure 6 show confocal laser 
scanning microscope (CLSM) images of the cells cultured 
on the bare MTFs, MTFs functionalized with hrBMP-2, and 
MTFs functionalized with hrBMP-2 and gentamicin, respec-
tively. The actin filaments (F-actin) were stained with phal-
loidin; thus, they are represented in red in the second row. 
Vinculin was stained with fluorescein isothiocyanate (FITC), 
in green, in the first row. The nucleus was stained with 
Adv. Mater. Interfaces 2019, 1801648
Figure 4. AFM images (height, phase, and height section) of MTF, MTF with hrBMP-2 100 ng mL−1, and MTF with hrBMP-2 100 ng mL−1 and loaded 
gentamicin. a) height, b) phase, and c) section of MTF substrates; d) height, e) phase, f) section of MTF with hrBMP-2 100 ng mL−1 substrate, showing 
an increase in the height, and g) height, similar to MTF with hrBMP-2 100 ng mL−1 sample, h) height and i) section image of MTF with hrBMP-2 
100 ng mL−1 and loaded with gentamicin.
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4,6-diamidino-2-phenylindole (DAPI) and is represented in 
blue in the merge images (third row), where all the labeled 
cell parts are shown. From the F-actin images can be seen 
that cultured cells in the three substrates exhibited a similar 
size and an arranged cytoskeleton with distinctive stress fibers 
inside the cytoplasm, especially at the border of the cells. How-
ever, the cell shape was different after 48 h of culture (third 
column). When the MTF was modified with hrBMP-2 (Figure 
S4, Supporting Information), the cell shape 
was more elongated if compared with cells 
cultured 48 h on the bare MTFs (Figure S5, 
Supporting Information) or hrBMP-2 and 
gentamicin (Figure 6). This cell shape and 
higher filopodia[51] means cells were inter-
acting better when hrBMP-2 was present on 
the surface and were well attached. This does 
not mean that cell attachment was not good 
on the other substrates, on which focal adhe-
sion points and a well-arranged cytoskeleton 
were as well present.
Focal adhesions allow cells to interact with 
the surrounding environment; vinculin can 
interconnect signals in the focal adhesions 
and is a key regulator.[52,53] In the vinculin 
staining images (first row), in all substrates, 
lots of green spots can be found. After 2 h 
of cell incubation on the substrates (first 
column), focal adhesions can also be perfectly 
distinguished, meaning that cells adhered 
well to the substrates from initial times, which 
would improve later cell proliferation.[49,52]
To study the influence of the hrBMP-2 
and gentamicin on cell proliferation, 
cells were cultured in substrates coated 
with hrBMP-2, coated with hrBMP-2 
and loaded gentamicin, and only loaded 
with gentamicin. hrBMP-2 was depos-
ited on the MTF from solutions with 10 
and 100 ng mL−1 hrBMP-2. Results are 
plotted in Figure 7. Data from MTFs coated 
with hrBMP-2 shown in the figure cor-
respond only to experiments performed 
with 100 ng mL−1 hrBMP-2. A comparison 
between the effects of hrBMP-2 10 and 
100 ng mL−1 on proliferation is shown in 
Figure S6 (Supporting Information). After 
7 days, cell culture was confluent, meaning 
that the surface was completely covered by 
cells forming a monolayer, and no differ-
ence could be distinguished between the 
MTF functionalized with hrBMP-2 and 
the bare MTF control. In Figure 7, we can 
observe that within the first day cells pro-
liferated at the same rate and cell density 
was the same for the four evaluated sub-
strates. After 2 days of culture, substrates 
with 100 ng mL−1 of hrBMP-2 showed an 
enhanced cell proliferation rate if com-
pared with cultures on MTFs and MTF 
with 10 ng mL−1 hrBMP-2 (p < 0.05).[54] After 4 days of 
culture, same differences were maintained, but cell den-
sity was also higher when hrBMP-2 concentration is low 
(10 ng mL−1) if compared with bare MTFs. As previously 
seen in Figure S5 (Supporting Information), cells were 
more expanded and showing higher filopodia in presence of 
hrBMP-2. When the interaction of the cell with the substrate 
is better, it is known that proliferation is also improved.[49,52]  
Adv. Mater. Interfaces 2019, 1801648
Figure 5. Release profile of gentamicin from MTF. Region I shows the burst release (the inset is 
a zoom of region I) and region II the sustainable release. The release is followed up to 35 days 
and followed by emission measurements at 455 nm. Results are shown as total gentamicin 
released in µg a) and percentage of released gentamicin b). Percentage of released gentamicin 
is calculated assuming that at day 35 a 100% of gentamicin has been released.
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If MTFs were functionalized with gentamicin and hrBMP-2, 
if compared with films only functionalized with hrBMP-2, dif-
ferences could be observed regarding the proliferation rates 
of MC3T3-E1 cells. At day 2, between samples with hrBMP-2 
or samples with hrBMP-2 and loaded with gentamicin, there 
was no difference on cell density, and in both cases the den-
sity was higher than cell density on bare MTFs. If cells were 
cultured for 4 days, there was a difference between samples 
without and with gentamicin. After 4 days of cell culture, for 
the MTF with hrBMP-2 and loaded gentamicin, proliferation 
rate decreased in a 46%, to values comparable to the prolifer-
ation observed for MTFs only loaded with gentamicin and for 
bare MTFs. The loading of the MTFs with gentamicin seems 
to cancel the positive action of hrBMP-2 on cell prolifera-
tion. Previous studies have shown that the interaction of gen-
tamicin with channels and receptors in the cell membrane[55] 
could lead to a decreased availability of the receptors of the 
BMP-2.
Alkaline phosphatase (AP) is one of the gene markers in 
the early stage of osteogenic differentiation.[56] Figure 8 shows 
the AP activity of the cells cultured on MTFs, MTFs with 
hrBMP-2, and MTFs with hrBMP-2 and gentamicin. After 
cells reached confluence, they were differentiated for 20 days 
and AP activity was measured at different steps to evaluate 
differences in differentiation rates. At day 2 and day 5 of dif-
ferentiation, there was no difference between the evaluated 
Adv. Mater. Interfaces 2019, 1801648
Figure 6. CLSM images of vinculin (first row), actin (second row), the merge of the actin, the vinculin, and the nucleus (third row) and the zoom of the 
merge image (fourth row) at 2 h (first column), 24 h (second column), and 48 h (third column) of growth of MC3T3-E1 cell line on MTF with hrBMP-2 
100 ng mL−1 and loaded with gentamicin at 63×.
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substrates and at day 20 all cells were differentiated and it was 
not possible to see any difference among substrates as well. 
Only at day 10 of cell culture in the differentiation medium, 
differences could be seen. For MTF coated with hrBMP-2, 
with or without gentamicin, the differentiation was more 
than double the differentiation on bare MTFs. This result was 
expected as the effectiveness of hrBMP-2 in promoting pre-
osteoblast differentiation has been demonstrated in a large 
number of works.[57–60]
2.4. Evaluation of the Antibacterial Properties of the hrBMP-2 
and Gentamicin Functionalized MTFs
The evaluation of the antibacterial capacity of MTFs loaded with 
gentamicin and hrBMP-2 functionalized was performed by 
incubating S. aureus for 24 h on top of the films.
Figure S7 (Supporting Information) shows colony-forming 
units (CFU) grown on the Luria–Bertani (LB) agar plates. Green 
ticks mean bacteria have grown on the agar plates and CFU 
counting is possible. Red crosses means that S. aureus have not 
grown on the LB agar plates. A total of 4.75 × 106 ± 5.8 × 105 
CFU are counted for MTF. In Figure 9a, a zoom of CFU grown 
on agar plates after growing in MTF is shown. However, when 
the MTF contains gentamicin, with or without hrBMP-2, bac-
teria were not grown, as can be seen in the zoom in Figure 9b. 
Figure 9c,d shows a cell observer image of S. aureus grown 
for 24 h on top of the MTF and the MTF functionalized with 
hrBMP-2 and gentamicin, respectively. The bare MTF surface 
was completely covered by the bacteria; the image shows black 
dots which are the coccus. The surface of the gentamicin loaded 
film shows very few dots; some bacteria become attached, but 
they are not alive, as seen in the agar plate culture, where no 
CFU were found.
3. Conclusion
Highly mesoporous titania films with a 30.7% porous volume 
have been shown here to encapsulate gentamicin in the 
porous matrix to an extent that the films display antibacterial 
properties. At physiological pH, the release of gentamicin in 
10 × 10−3 m PBS shows a two-step release profile. The porous 
structure of the titania results in an initial burst release of gen-
tamicin within the first 6 h with a liberation of around the 36% 
of the total released gentamicin. The burst release is followed 
by a slow release of the remaining gentamicin that last over 
weeks. This release profile fits with the initial requirements 
of avoiding the formation of bacteria colonies on the implant 
while surgery is conducted releasing most of the gentamicin 
during first hour, while the rest of the gentamicin is released in 
lower doses for a period lasting weeks avoiding infection while 
the tissue is being reconstituted.
MTFs functionalized with hrBMP-2 improve MC3T3-E1 cell 
adhesion and proliferation. However, when the MTF is also 
loaded with gentamicin, proliferation rate is diminished but 
still is comparable to the proliferation rate for bare MTFs. Cell 
differentiation is not affected by the presence of gentamicin, 
and when MTFs are functionalized with hrBMP-2, the differen-
tiation rate increases at day 10 to the double of the rate of cells 
cultured onto MTFs.
The efficacy of the functionalized substrates against 
S. aureus bacterial infection is shown seeding 1000 CFU of 
bacteria on the gentamicin-loaded MTFs. Bacteria do not pro-
liferate, hinting the potential of the gentamicin-loaded MFT for 
avoiding S. aureus infections.
Overall, our work shows the potential of mesoporous titania 
for antibiotic loading and delivery for avoiding bacterial infec-
tion. The release profile of gentamicin matches the require-
ment of a burst release during operation and immediately after 
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Figure 7. Proliferation of MC3T3-E1 preosteoblasts cultured on MTFs, 
MTFs with gentamicin, MTFs with hrBMP-2 100 ng mL−1 and with 
hrBMP-2 100 ng mL−1, and gentamicin substrates for 2 h and 1, 2, and 
4 days. * means that the difference is statistically significant.
Figure 8. Alkaline phosphatase activity after 2, 5, 10, and 20 days of 
MC3T3-E1 preosteoblastic cell culture in osteogenic medium on MTF, 
MTF with hrBMP-2 100 ng mL−1, and MTF with gentamicin and BMP 
100 ng mL−1 substrates. * means the difference is statistically significant.
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followed by a sustainable release of gentamicin until the bone 
tissue is reconstituted. The additional modification of the MTF 
with hrBMP-2 has a positive effect on proliferation and cell 
adhesion that seems to overcome negative effects from gen-
tamicin on osteoblasts.
4. Experimental Section
Mesoporous Titania Film Synthesis and Characterization: Mesoporous 
titania films with a pore size of 5.7 nm were synthesized by sol–gel 
chemistry and the EISA method. Rounded glass slides with 14 mm 
diameter and 0.13–0.16 mm thickness from Thermo Fisher Scientific 
were used for film deposition. Pluronic F-127 (EO106PO70EO106) was 
used as a structure-directing agent.
For sol preparation, titanium(IV) chloride (≥99.0%, TiCl4), ethanol 
absolute (Synthesis grade, EtOH), Pluronic F-127, and nanopure water 
(H2O) were mixed in a molar proportion of TiCl4:EtOH:F-127:H2O 
= 1:40:0.0056:10. The titania precursor was prepared first, adding TiCl4 
to EtOH under vigorous stirring. When this solution was dropped to 
room temperature, the F-127 and H2O were added and left stirring 
for 10 min to obtain a homogeneous solution. All the reagents were 
purchased from Sigma Aldrich except for the ethanol, purchased from 
Scharlau.
To produce uniform films, 30 µL of the sol, previously mixed with 
EtOH in a volume proportion of sol:EtOH = 2:1, was spin-coated at 
68 rpm for 30 s in the glass slices using a SCC-200 spin coater from 
Novocontrol Technologies. Taking advantage of EISA[61] after the sol 
deposition, films were placed for 30 min in a humidity chamber with 
a controlled relative humidity of 50%, obtained with saturated calcium 
nitrate (Ca(NO3)2) solution in water. Then, they were subjected to a 
gentle thermal treatment: 30 min at 60 °C and another 30 min at 130 °C. 
Finally, they were calcined; first, heating up with a ramp of 1 °C min−1 
and then keeping them at 350 °C for 2 h.
For pore visualization, a JEOL JEM-1400PLUS transmission electron 
microscope equipped with a Gatan US1000 CCD camera was used. 
Films were scratched to obtain a powder, which was deposited on 
carbonated copper grids with a drop of pure ethanol. Film topography 
was visualized with a field emission scanning electron microscopy 
(FE-SEM) Carl Zeiss NTS Supra 40 at the Advanced Microscopy Center 
FCEN-UBA.
Ellipsometric and EEP measurements of MTFs were performed in 
a SOPRA GES5A ellipsometer, using samples previously washed with 
absolute ethanol and dried. Film thickness and refractive index values 
were obtained from the ellipsometric parameters Ψ and Δ under dry 
air flux containing variable water vapor pressure P; P/P0 was varied 
from 0 to 1 (P0 being the saturation water vapor pressure at 25 °C). 
Water volume adsorbed at each P/P0 value was determined by 
modeling the obtained refractive index according to a three-component 
(water−air−oxide) Bruggeman effective medium approximation. 
Adsorption–desorption isotherms were obtained by plotting the water 
volume adsorbed by the porous film at each P/P0. The pore size 
distribution was obtained from the isotherms using the Kelvin equation, 
taking into account the water contact angle in the film.[62] Water contact 
angles required for such calculations were determined using a Ramé-Hart 
190 CA equipment.
Prior to its use, MTFs were cleaned as follows; they were immersed in 
absolute ethanol for 30 min, 15 min in distilled water, dried with N2 gun, 
and sterilized for 1 h under UV light.
2D-SAXS patterns were obtained at the Austrian SAXS beamline at 
the Elettra synchrotron (Trieste, Italy), using a 1.54 Å (8 keV) incidence 
X-ray beam. The sample was placed at 82.88 cm from a pixel detector 
(Pilatus 1M) on a rotation stage, which was allowed to set the glancing 
angle between the incident radiation and the sample to 3°.[63] The 
samples were prepared onto coverslips to allow measurements in Laue 
geometry. The angular scale of the detector was calibrated with Ag 
behenate as the reference pattern.
Nanomechanical tests were performed using a triboindenter 
(Hysitron-TI-950), equipped with a Berkovich tip and a 2D-axis 
transducer. The value of the elastic modulus (Er) was extracted from 
Adv. Mater. Interfaces 2019, 1801648
Figure 9. CFU counting after S. aureus growth on agar plates for 24 h and cell observer images of S. aureus growth on MTF and MTF functionalized 
with hrBMP-2 and gentamicin. a) Zoom of Sample 1 in Figure S6 (Supporting Information), agar plates with cultured S. aureus for 24 h on MTF 
in 1/10 000 dilution and b) zoom of Sample 1 in Figure S6 (Supporting Information), of agar plates with cultured S. aureus for 24 h on MTF with 
hrBMP-2 and gentamicin in 1/1 dilution. Cell observer images of 24 h of growth of S. aureus on c) MTF and d) MTF with hrBMP-2 and gentamicin 
substrates.
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nanoindentation tests. Indentation measurements were performed 
ten times using partial load–unload function and the Oliver–Pharr 
method[64] and then corrected following the method described by Coy 
et al.[65] Measurements were performed after 120 s of drift correction 
and shallow calibration (5–30 nm) of the indenter on commercially 
available fused quartz (69.6 GPa).
Deposition of Bone Morphogenetic Protein 2: A drop of 100 µL of 
human recombinant bone morphogenetic protein 2 (Sigma Aldrich) at 
concentrations of 10, 100, and 1000 ng mL−1 in PBS (Sigma Aldrich) 
(10 × 10−3 m) was left adsorbing for 1 h on top of MTFs.
Water contact angles were measured for hrBMP-2 adsorbed on MTFs 
and gentamicin loading using Drop Shape Analyzer—DSA100 Kruss 
equipment. Three different films measured.
The presence of sulfur after hrBMP-2 immobilization and gentamicin 
loading was confirmed by XPS atomic composition analysis. A SPECS 
Sage HR 100 spectrometer equipped with a 100 mm mean radius 
PHOIBOS analyzer and a non-monochromatic X-ray source (Mg Kα line 
of 1253.6 eV energy and 250 W), placed perpendicular to the analyzer 
axis and calibrated using the 3d5/2 line of Ag, with a full width at half 
maximum of 1.1 eV was used. The selected resolution for high-
resolution spectra was 15 eV of pass energy and 0.15 eV per step. All 
measurements were made in an ultrahigh vacuum chamber at a pressure 
of around 8 × 10−8 mbar. An electron flood gun was used to neutralize 
for charging. Measurements were conducted directly on the films, which 
were previously washed with absolute ethanol. The analysis of spectra 
was done with CasaXPS 2.3.15dev87 software. Satellite removal and 
Shirley background subtraction were applied. Binding energies were 
calibrated assigning to the C 1s CC peak 285 eV, and peaks were fitted 
with Gaussian–Lorentzian line shapes. The MTF exposed to the lowest 
hrBMP-2 concentration (10 ng mL−1) was used for XPS characterization.
AFM images of samples without any functionalization, functionalized 
with hrBMP-2 100 ng mL−1 and MTFs functionalized with 100 ng mL−1 
hrBMP-2 and loaded with gentamicin were obtained with a Nanowizard 
II AFM (JPK, Berlin, Germany). Images were produced in air in 
tapping mode using the tip TESP-V2 (Bruker, AFM probes) which had 
a spring constant of 40 N m−1 and a resonant frequency in the range 
of 280–320 kHz. Average roughness Ra was calculated, which gives the 
deviation in height.[66–68]
Gentamicin Loading and Release: Gentamicin sulfate salt was 
purchased from Sigma Aldrich. For gentamicin loading, MTFs were 
immersed for 24 h in a 0.2 mg mL−1 gentamicin solution in distilled water. 
For films functionalized with hrBMP-2, gentamicin was loaded after the 
adsorption of the growth factor. To remove gentamicin deposited on top 
of the MTFs and not in the pores, MTFs were immersed once in distilled 
water prior to their use.
O-phthaldialdehyde (OPA) reagent was used to study the gentamicin 
release.[69,70] Boric acid was dissolved in distilled water to obtain a 
concentration of 0.4 m and pH was adjusted to 10.4 with potassium 
hydroxide solution. OPA reagent was prepared according to the following 
procedure: 0.2 g of OPA was dissolved in 1 mL of methanol and the 
solution was mixed with 19 mL of a 0.4 m boric buffer. Then, 0.4 mL 
of 2-mercaptoethanol was added and the pH was adjusted to 10.4 with 
the potassium hydroxide solution. This reagent was kept in the dark at 
4 °C until its use in the following day. Samples and the 2-propanol were 
mixed in 1:1 proportion in volume and vortexed. Then, the OPA reagent 
was added in the same proportion and the solution was vortexed 
again.[69,70] For 15 min, prior to measurement, the solutions were heated 
at 60 °C to catalyze the reaction. All the reagents were purchased from 
Sigma Aldrich, except 2-propanol, which was obtained from Fisher.
Gentamicin release was studied by placing the loaded MTFs in 
a 24 multiwell dish. 1 mL of 10 × 10−3m PBS was added to the wells 
with the sample. The release was measured at 15 and 30 min, at 1, 2, 
4, and 6 h, and at 2, 3, 6, 7, 10, 21, 28, and 35 days. PBS solution was 
removed for each measurement from the well and replaced with fresh 
PBS. Gentamicin calibration curve was performed with concentrations 
of gentamicin ranging from 0 to 2 µg mL−1 containing seven points. The 
calibration curve can be described with the following equation: y  =  6.49 
+  21.26 x, where y is the emission of the OPA–gentamicin complex at 
450 nm and x is the gentamicin concentration in µg mL−1 and has an 
R2 of 0.997.
The fluorescent complex of gentamicin with OPA has its maximum 
absorption at 340 nm and the emission at 450 nm. Fluorescence was 
collected at a Thermo Scientific Varioskan Flash Multimode Reader.
S. aureus Culture and Antimicrobial Susceptibility Assay: S. aureus is 
Gram-positive spherical bacteria and the RN4220 strain used in this 
work is resistant to erythromycin. It was cultured in LB broth from 
Lennox with 10 µg mL−1 erythromycin overnight at 37 °C under constant 
shaking at 200 rpm.
After 24 h of growth in LB Broth, the bacteria were centrifuged at 
2500 rpm for 5 min and washed in 10 × 10−3 m PBS with 150 × 10−3 m 
NaCl (pH 7.4) three times. They were resuspended in 10 × 10−3 m PBS 
and optical density was adjusted to 0.257 at 600 nm with an UV–VIS 
Varian Cary 50 spectrophotometer, estimated to give 3 × 108 CFU per 
milliliter. The bacteria solution was diluted in LB Broth with 10 µg mL−1 
erythromycin (Sigma Aldrich). Films were added into 24 multiwell dishes 
and 1 mL of LB Broth containing 1000 CFU was added on top of the 
films and incubated for 24 h at 37 °C. Then, the media was removed and 
samples were removed from the wells. To detach the adhered bacteria, 
samples were vortexed at 30 000 rpm for 1 min inside sterile 50 mL 
centrifuge tubes with 10 mL of 10 × 10−3 m PBS. Three dilutions were 
performed in PBS to culture 100 µL onto sterile LB Agar (Lennox) with 
10 µg mL−1 erythromycin. Bacteria were diluted in 1/1, 1/10, and 1/100 
for films containing gentamicin and for bare MTF control dilutions were 
1/10 000, 1/100 000, and 1/1000 000, respectively. Plates were placed 
into an incubator at 37 °C to allow colonies to grow until visual counting 
was possible (≈24 h).
Cell Culture, Adhesion, Proliferation, and Differentiation: The 
MC3T3-E1 preosteoblastic cell line was purchased from Sigma Aldrich. 
Preosteoblasts were maintained in alpha minimum essential medium 
(α-MEM) containing 10% fetal bovine serum (FBS), 1% penicillin–
streptomycin, and 2 × 10−3 m l-glutamine. They were subcultured every 
3 days until passage 40. For cell differentiation, the previous medium 
was supplemented with 50 µg mL−1 l-ascorbic acid, and 2 × 10−3 m 
β-glycerophosphate. All the reagents were purchased from Sigma Aldrich.
MTFs were sterilized for 1 h under UV light. The solutions containing 
the hrBMP-2 and gentamicin were filtered with 0.22 µm filters prior 
to their use, inside the biosecurity 2 chamber. All the substrates were 
prepared under sterile condition prior to their use for cell culture 
experiment.
To confirm cell adhesion to the substrates confocal laser scanning 
microscopy (Zeiss LSM510), observations were performed after F-actin, 
focal adhesions, and nucleus labeling with actin cytoskeleton and focal 
adhesion staining kit (FAK100, Millipore). Briefly, after reaching the 80% 
confluence, cells were trypsinized and resuspended in fresh medium to 
a final cell density of 3 × 104 cells mL−1. About 1 mL of cell suspension 
was added into each well of 24 multiwell cell culture plates with MTFs, 
gentamicin loaded MTFs, hrBMP-2 functionalized MTFs, and hrBMP-2 
functionalized MTFs loaded with gentamicin. After culturing for 2 h, 
24 h, 48 h, and 7 days, cells were fixed with a 4% paraformaldehyde 
solution. Cells were first permeabilized with 0.1% Triton-X100 (Sigma 
Aldrich) for 4 min at room temperature. Then, cells were incubated 
in dilute antivinculin primary antibody for 1 h at room temperature, 
followed by three times wash for 5−10 min each with wash buffer (PBS 
with 0.05% Tween-20 (Sigma Aldrich)), followed by 1 h further incubation 
with an FITC-conjugated secondary antibody and tetramethylrhodamine 
(TRITC)-conjugated Phalloidin at room temperature. After three times 
rinsing with wash buffer, cells were incubated with DAPI for 3 min at 
room temperature, followed by a three time wash.
Cell proliferation colorimetric analysis was performed with the Cell 
Counting Kit-8 (CCK-8) (Sigma Aldrich) containing WST-8 [2-(2-methoxy-
4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, 
monosodium salt], a nontoxic dye used for continuous cell culturing. 
When cells reached 80% confluence, they were trypsinized and 
resuspended in fresh medium to a final cell density of 3 × 104 cells mL−1. 
1 mL of cell suspension was added into each well of 24 multiwell 
cell culture plates with the functionalized MTFs inside. Cells cultured 
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on the films were refreshed with 250 µL 10% v/v of CCK-8 containing 
medium, and after 2 h of incubation at 37 °C two aliquots of 100 µL of 
each sample were placed into a 96-well cell plate. The absorbance was 
measured using a plate reader (GENios Pro, Tecan) equipped with a 
450 nm filter. Measurements were done by triplicate at 2 h, 24 h, 48 h, 
and 7 days.
Proliferating osteoblasts show AP activity in the stage of extracellular 
matrix maturation, being greatly enhanced during in vitro bone 
formation. AP activity is therefore a feasible marker for differentiating 
and mineralizing osteoblastic formation.[71] For AP quantification, 1 mL 
of cells was seeded with a density of 5 × 104 cell mL−1 in a 24 multiwell 
dish. After 4 days of growth, cells were cultured in osteogenic medium 
for 20 days following the differentiation during this time.
AP was quantified with the StemTAG Alkaline Phosphatase Activity 
Assay Kit from Cell Biolabs Inc. The AP catalyzes the conversion of 
p-nitrophenyl phosphate (pNPP) to p-nitrophenol (pN). pN is a bright 
yellow-colored compound which has maximum absorbance at 405 nm. 
The rate of increase in absorbance from pNPP (colorless) to pN (color) 
is directly proportional to the AP enzyme activity in the serum sample. 
Following the indications of the fabricant, a calibration curve with 
pN at concentrations ranging from 0.5 × 10−3 to 0.9766 × 10−6 m was 
performed. The calibration curve to determine the total amount of pN 
was obtained from ten points and is y  =  0.044  +  7.51 x, where y is the 
absorbance at 405 nm and x is the pN concentration in (× 10−3) m with 
an R2 of 0.999. Cells were cleaned twice with cold PBS and lysated with 
250 µL lysis buffer for 10 min at 4 °C. Lysated cells have to be spin down 
at 12.000 × g for 10 min and the supernatant must be kept. 1:1 relation 
in volume of cell lysate and pNPP were incubated for 15 min at 37 °C. To 
stop the reaction, the same proportion in volume of stop solution was 
added and shaked for 30 s.
The Bradford assay was carried out to quantify the protein in the 
lysate and normalize the results. One part of the protein sample was 
mixed with 30 parts of the Bradford Reagent, which consists of a 
dye, Brilliant Blue G that forms a complex with proteins, shifting the 
absorption maximum from 465 to 595 nm. Bovine serum albumin (BSA, 
Sigma Aldrich) was used as standard protein. The calibration curve with 
five points ranging from 1 to 2 mg mL−1 of BSA is =  0.37  +  0.13 x, 
where y is the absorbance at 595 nm and x is the total amount of 
protein in mg mL−1 with an R2 of 0.983. Absorbance measurements were 
performed at a Thermo Scientific Varioskan Flash Multimode Reader.
All the statistical analysis concerning analysis of variance (ANOVA) 
was done using OriginPro 2016 software. Fisher’s tests were performed 
to determine statistically significant differences with p < 0.05.
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